ProShare Advisors
MRNA icon

ProShare Advisors’s Moderna MRNA Stock Holding History

ProShare Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.95M Sell
70,621
-721
-1% -$37.3K 0.01% 561
2026
Q1 		$3.62M Sell
71,342
-14,122
-17% -$659K 0.01% 607
2025
Q4 		$2.52M Buy
85,464
+8,029
+10% +$218K ﹤0.01% 674
2025
Q3 		$2M Buy
77,435
+2,367
+3% +$66K ﹤0.01% 696
2025
Q2 		$2.07M Buy
75,068
+3,183
+4% +$83.8K ﹤0.01% 685
2025
Q1 		$2.04M Buy
71,885
+1,632
+2% +$57.9K ﹤0.01% 672
2024
Q4 		$2.92M Sell
70,253
-359,045
-84% -$17.2M 0.01% 619
2024
Q3 		$28.7M Buy
429,298
+27,750
+7% +$2.55M 0.07% 224
2024
Q2 		$47.7M Sell
401,548
-43,073
-10% -$5.45M 0.13% 142
2024
Q1 		$47.4M Buy
444,621
+78,017
+21% +$7.86M 0.13% 148
2023
Q4 		$36.5M Sell
366,604
-61,975
-14% -$5.21M 0.11% 173
2023
Q3 		$44.3M Buy
428,579
+53,937
+14% +$6.02M 0.14% 135
2023
Q2 		$45.5M Sell
374,642
-29,289
-7% -$3.91M 0.13% 132
2023
Q1 		$62M Buy
403,931
+37,368
+10% +$6.16M 0.19% 114
2022
Q4 		$65.8M Sell
366,563
-51,985
-12% -$8.5M 0.23% 102
2022
Q3 		$49.5M Sell
418,548
-83,002
-17% -$12.6M 0.19% 108
2022
Q2 		$71.6M Sell
501,550
-260,438
-34% -$37.2M 0.24% 107
2022
Q1 		$131M Sell
761,988
-28,621
-4% -$4.82M 0.28% 102
2021
Q4 		$201M Buy
790,609
+246,204
+45% +$72M 0.39% 50
2021
Q3 		$210M Buy
544,405
+87,676
+19% +$32.3M 0.59% 26
2021
Q2 		$107M Sell
456,729
-9,111
-2% -$1.63M 0.31% 102
2021
Q1 		$61M Buy
465,840
+70,703
+18% +$10.2M 0.19% 127
2020
Q4 		$41.3M Buy
395,137
+50,961
+15% +$5.16M 0.15% 141
2020
Q3 		$24.4M Buy
344,176
+277,285
+415% +$19.3M 0.11% 159
2020
Q2 		$4.29M Buy
66,891
+17,274
+35% +$946K 0.02% 422
2020
Q1 		$1.49M Sell
49,617
-27,384
-36% -$630K 0.01% 526
2019
Q4 		$1.51M Buy
+77,001
New +$1.37M 0.01% 681

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

ProShare Advisors's MRNA Position: Q2 2026 in Review

ProShare Advisors reduced its Moderna (MRNA) stake by 1% in Q2 2026, selling an estimated $37.3K and leaving 70,621 shares worth $4.95M. The position accounts for 0.01% of the portfolio, ranked #561.

ProShare Advisors first reported a position in MRNA in Q4 2019 and has held it in 27 quarters since. The position peaked at $210M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • ProShare Advisors held 70,621 shares of Moderna worth $4.95M as of Q2 2026.
  • ProShare Advisors sold 721 Moderna shares in Q2 2026, an estimated $37.3K.
  • Moderna made up 0.01% of ProShare Advisors's portfolio in Q2 2026, its #561 holding.
  • ProShare Advisors first reported a position in Moderna in Q4 2019 and has held it in 27 quarters since.
  • ProShare Advisors's Moderna position peaked at $210M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.